0.00%
Today
Loading 1D prices…
Company profile
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
EmeryVille, CA, United States
Employees
113
Fiscal year end
1231
CIK
1785279
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ATYRaTyr Pharma Inc. Common Stock | $42.2M | $190K | -39009.47% | -$0.80 | -1.60% | Hold |
| GNTAGenenta Science S.p.A. American Depositary Shares | $40.5M | — | — | -$0.33 | -2.32% | Unrated |
| TVGNTevogen Inc. Common Stock | $47.9M | $0.00 | — | -$8.08 | +0.96% | Unrated |
| TILInstil Bio Inc. Common Stock | $50.1M | $0.00 | — | -$10.70 | +0.27% | Hold |
| ELUTElutia Inc. Class A Common Stock | $35.9M | $12.3M | +434.23% | $0.87 | +1.25% | Buy |